Andrew Grupe

Quest Diagnostics (United States)

Papers

1

Total Citations

26

H-Index

1

About

Andrew Grupe is a clinical molecular biologist whose work has been pivotal in advancing genomic surveillance of infectious diseases, most notably during the COVID-19 pandemic. His primary research focuses on the development and validation of high-throughput sequencing workflows for clinical laboratories, enabling rapid and accurate monitoring of viral evolution. Grupe’s most cited work, a 2022 study on a SARS-CoV-2 whole genome sequencing protocol, has garnered 26 citations and provides a critical framework for identifying diagnostic and therapeutic targets by tracking emerging mutations. This contribution has directly supported public health efforts to control COVID-19 through more informed strategies. By translating next-generation sequencing technologies into practical clinical tools, Grupe has helped bridge the gap between cutting-edge genomics and real-time pandemic response, demonstrating how robust laboratory methods can empower researchers and clinicians alike. His achievements underscore the importance of scalable, validated workflows in the fight against emerging viral threats.

Research Focus

Key Achievements

1
H-Index
1
Papers
26
Total Citations
26
Avg Citations/Paper
🏆 Most Cited Paper
Development and validation of a high throughput SARS-CoV-2 whole genome sequencing workflow in a clinical laboratory
26 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 14
🏛 Institutions: Quest Diagnostics (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago